Barclays PLC Raises Holdings in Wave Life Sciences Ltd. (NASDAQ:WVE)

Barclays PLC boosted its position in Wave Life Sciences Ltd. (NASDAQ:WVE) by 171.1% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 159,241 shares of the company’s stock after purchasing an additional 100,498 shares during the quarter. Barclays PLC’s holdings in Wave Life Sciences were worth $1,307,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in WVE. Charles Schwab Investment Management Inc. boosted its holdings in shares of Wave Life Sciences by 209.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 844,617 shares of the company’s stock worth $6,926,000 after purchasing an additional 571,345 shares during the last quarter. FMR LLC lifted its position in Wave Life Sciences by 174.5% during the third quarter. FMR LLC now owns 1,540,190 shares of the company’s stock worth $12,630,000 after buying an additional 979,110 shares in the last quarter. Maven Securities LTD acquired a new position in Wave Life Sciences during the third quarter worth $6,970,000. Privium Fund Management B.V. acquired a new position in Wave Life Sciences during the third quarter worth $400,000. Finally, Moody Aldrich Partners LLC grew its holdings in Wave Life Sciences by 69.0% in the 3rd quarter. Moody Aldrich Partners LLC now owns 303,062 shares of the company’s stock valued at $2,485,000 after buying an additional 123,703 shares in the last quarter. Hedge funds and other institutional investors own 89.73% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on WVE. StockNews.com lowered Wave Life Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, November 13th. Wells Fargo & Company lifted their target price on shares of Wave Life Sciences from $11.00 to $22.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 16th. B. Riley increased their price target on shares of Wave Life Sciences from $19.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, November 4th. Raymond James upgraded shares of Wave Life Sciences from an “outperform” rating to a “strong-buy” rating and raised their price target for the stock from $13.00 to $22.00 in a report on Wednesday, October 16th. Finally, Royal Bank of Canada upped their price objective on Wave Life Sciences from $7.00 to $15.00 and gave the company a “sector perform” rating in a report on Monday, October 21st. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.22.

Wave Life Sciences Stock Performance

Shares of WVE stock opened at $12.90 on Friday. The firm has a market cap of $1.97 billion, a P/E ratio of -11.62 and a beta of -1.21. The firm’s 50 day moving average price is $14.41 and its 200-day moving average price is $9.25. Wave Life Sciences Ltd. has a one year low of $3.50 and a one year high of $16.74.

Insider Buying and Selling at Wave Life Sciences

In other Wave Life Sciences news, CEO Paul Bolno sold 50,000 shares of the stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $15.00, for a total transaction of $750,000.00. Following the sale, the chief executive officer now directly owns 217,351 shares in the company, valued at $3,260,265. This represents a 18.70 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Chris Francis sold 208,836 shares of the firm’s stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $13.67, for a total transaction of $2,854,788.12. The disclosure for this sale can be found here. Insiders have sold a total of 436,544 shares of company stock valued at $6,271,569 over the last quarter. 29.10% of the stock is owned by company insiders.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.